English
Regional settings| Spread | 0.17 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 102.4 |
| Open | 103.33 |
| 1-Year Change | -20.72% |
| Day's Range | 101.64 - 104.02 |
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and Haoyuan.
BRIEF: For the fiscal year ended 02 January 2022, PerkinElmer, Inc. revenues increased 34% to $5.07B. Net income before extraordinary items increased 30% to $943.3M. Revenues reflect Diagnostics segment increase of 42% to $2.93B, Discovery & Analytical Solutions segment increase of 24% to $2.14B, Other Foreign segment increase from $839.2M to $1.93B, United States segment increase of 61% to $2.05B, United Kingdom segment increase of 15% to $417.2M.
Common Stock $1 Par, 05/11, 300M auth., 112,761,872 issd., Insiders own 1.01%. IPO 5/65, 150,000 shares @ $27.50 by Kidder Peabody & Co. 6/01, 5/92, 2-for-1 stock splits. *11/01, Company acquired Packard BioScience Company @ 0.311 shares (21,363,882 shares issd.).
